AbCellera Biologics Inc. has added Dr. Stephen Quake, a leading figure in single‑molecule biophysics and AI‑driven diagnostics, to its board of directors. Dr. Quake earned a D.Phil. from Oxford and has authored more than 300 papers and holds over 80 patents. His previous roles at Stanford, Caltech, and the Chan Zuckerberg Biohub, where he helped launch a $600 million research program, give him deep expertise in the technologies that underpin AbCellera’s antibody‑discovery platform.
The appointment comes as AbCellera continues its shift from a platform partner to a clinical‑stage biotech. In the third quarter of 2025, the company generated $9.0 million in revenue, up 38 % from $6.5 million in the same period a year earlier, driven by increased demand for its AI‑powered discovery services. However, the net loss widened to $57.1 million from $51.1 million in Q3 2024, reflecting heavy investment in its internal pipeline and a new clinical manufacturing facility. For the full year 2024, revenue totaled $28.8 million, down 24 % from $38.0 million in 2023, while the net loss expanded to $162.9 million from $146.4 million a year earlier. Despite these losses, the company’s cash position remains robust, with $650 million in cash and equivalents and more than $800 million in total liquidity, giving it the runway to fund its clinical programs.
Dr. Quake’s expertise in microfluidics, single‑cell analysis, and genomics aligns closely with AbCellera’s core technology, which uses AI to identify therapeutic antibodies from vast libraries. His presence on the board is expected to strengthen scientific governance and accelerate the company’s internal pipeline, particularly the Phase 1 programs ABCL635 and ABCL575. The board now includes a broader mix of scientific leaders, which should enhance oversight of the company’s transition and help prioritize research investments.
The announcement followed a mixed earnings release that saw revenue beat expectations but a widening net loss. Investors have been cautious, focusing on the company’s continued losses and the need to demonstrate clinical success. The appointment was viewed as a positive governance move, but it did not offset concerns about the company’s profitability trajectory, which remains a key focus for stakeholders.
CEO Carl Hansen said, “We are pleased to welcome Dr. Quake to AbCellera’s Board of Directors. His presence reinforces our commitment to excellence in science and technology and will help us accelerate our pipeline as we transition to a clinical‑stage biotech.”
With a strong liquidity base and a board that now includes one of the most respected scientists in the field, AbCellera is positioned to navigate the next phase of its development. The company will continue to invest in its pipeline and manufacturing capabilities while monitoring the financial impact of these investments as it moves toward clinical milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.